Perspective Therapeutics, Inc.
Financials
Valuation Metrics
Perspective Therapeutics, Inc.'s Market Cap is $118M. At end of 2025 it was $203M. Ranked #3042 of 3,116 in US market (top 98%), #1636 of 1,644 on NYSE (top 100%), #197 of 203 in Health Care Equipment & Services (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $118M | US#3,042/3,116 Sec#197/203 |
| Revenue | $366000.00 | US#2,853/3,116 Sec#200/203 |
| Net Income | $-116M | US—/3,116 Sec—/203 |
| Total Assets | $392M | US#2,841/3,116 Sec#167/203 |
| Net Assets | $324M | US#2,474/3,116 Sec#142/203 |
| Employees | 165 | US#2,513/3,116 Sec#175/203 |
| Value | ||
| P/B | 0.36x | US#66/3,116 Sec#4/203 |
| P/S | 322.51x | US#2,967/3,116 Sec#203/203 |
| FCF Yield | -102.67% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -35.95% | US#2,596/3,116 Sec#160/203 |
| ROA | -29.70% | US#2,872/3,116 Sec#187/203 |
| Op. Margin | -34216.39% | US#2,854/3,116 Sec#200/203 |
| Financial Health | ||
| Debt Ratio | 21.05% | US#235/3,116 Sec#22/203 |
| Total Debt | $4M | US#2,910/3,116 Sec#197/203 |
| FCF | $-121M | US#2,677/3,116 Sec#192/203 |
| Cash | $48M | US#2,578/3,116 Sec#165/203 |
| Current Ratio | 6.61x | US#365/3,116 Sec#24/203 |
| Performance | ||
| 1Y Return | -62.09% | US#2,957/3,116 Sec#195/203 |
| 1M Return | -62.50% | US#3,104/3,116 Sec#202/203 |
| From 52W High | -83.20% | US#3,063/3,116 Sec#200/203 |
| 1Y MDD | -81.68% | US#3,035/3,116 Sec#198/203 |
| Trading | ||
| Volume | 2,024,473 shares | US#861/3,116 Sec#45/203 |
| Trading Value | $2M | US#2,836/3,116 Sec#184/203 |
| Per Share | ||
| EPS | $-1.02 | US—/3,116 Sec—/203 |
| BPS | $2.84 | US#2,498/3,116 Sec#165/203 |
Company Info
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.